University of North Carolina at Chapel Hill School of Medicine

Medications

Trial results of new drug for generalized myasthenia gravis

Argenx, a Belgium pharmaceutical company, recently announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living ...

Health

The skinny on fat: Debate rages on pros, cons of low-fat diet

(PhysOrg.com) -- In recent years a fierce debate has raged among nutrition experts over the wisdom of prevailing dietary guidelines that emphasize eating less saturated fat. Two experts from the UNC Department of Nutrition ...

Oncology & Cancer

New models of kidney cancer may drive immunotherapy research

University of North Carolina Lineberger Comprehensive Cancer Center scientists have developed preclinical laboratory models of the two most common types of kidney cancer, an advancement that may aid in the evaluation of novel ...

page 7 from 31